Table 3.
Mixed effect modelling of changes in antibody concentrations 11 months after second dose
|
Variables |
Model 1: Total Anti-Spike antibody β (95 % CI) |
Model 2: Anti-Spike IgG β (95 % CI) |
Model 3: Anti-RBD IgG β (95 % CI) |
|---|---|---|---|
|
Fixed effects |
|
|
|
|
Days after the second dose |
−0.0032 (−0.0043, –0.0021)* |
−0.0044 (−0.0054, 0.0034)* |
−0.0049 (−0.0061, –0.0038)* |
|
Female sex (vs. male sex) |
−0.0046 (−0.11, 0.11) |
−0.033 (−0.13, 0.064) |
0.0024 (−0.12, 0.12) |
|
Age (years) |
−0.0060 (−0.011, –0.00058)* |
−0.0079 (−0.013, –0.0031)* |
−0.0070(−0.013, –0.0012)* |
|
Racialized (vs. white) |
−0.0097 (−0.18, 0.16) |
0.085 (−0.057, 0.23) |
0.073 (−0.099, 0.24) |
|
(BMI: 18.5 to <25 kg m−2) vs. others |
−0.20 (−0.49, 0.093) |
0.21 (0.0054, 0.41)* |
0.23 (−0.015, 0.48) |
|
(BMI ≥25 kg m−2) vs. others |
−0.0073 (−0.29, 0.28) |
0.37 (0.15, 0.58)* |
0.38 (0.13, 0.64)* |
|
Tobacco use |
−0.16 (−0.42, 0.11) |
−0.12 (−0.32, 0.085) |
−0.12 (−0.37, 0.12) |
|
Vaccine type (BNT162b2 vs. mRNA-1273) |
−0.30 (−0.44,–0.17)* |
−0.15 (−0.27, –0.031)* |
−0.21 −0.36,–0.066)* |
|
Shorter Dose 1-to-Dose 2 interval (<35 days) |
−0.29 (−0.40,–0.18)* |
0.022 (−0.076, 0.12) |
−0.075 (−0.19, 0.044) |
|
Medical History |
|
|
|
|
Hypertension |
−0.18 (−0.38, 0.0088) |
−0.0062 (−0.16, 0.15) |
−0.038 (−0.22, 0.15) |
|
Diabetes |
−0.047 (−0.47, 0.38) |
−0.078 (−0.46, 0.30) |
−0.066 (−0.52, 0.39) |
|
Asthma |
0.077 (−0.061, 0.21) |
0.10 (−0.019, 0.23) |
0.13 (−0.021, 0.27) |
|
Liver disease |
−0.082 (−0.51, 0.34) |
0.013 (−0.36, 0.39) |
−0.00088 (−0.46, 0.45) |
|
Cancer |
−0.14 (−0.50, 0.22) |
0.033 (−0.28, 0.35) |
−0.012 (−0.40, 0.37) |
|
Random component |
|
|
|
|
Intercept/constant (95 % CI) |
2.54e-14 (0) |
0.17 (0.15, 0.20) |
0.25 (0.21, 0.29) |
β (95 % CI): Effects estimate (95 % confidence interval); β values estimates were shown to two significant figures; p values were shown to three decimal places, se: standard error; BMI: Body Mass Index (Kg m−2).
*=P<0.05.